Medtronic received information via literature regarding prospective evaluation of the clinical and hemodynamic performance of the mosaic bioprosthesis.All data were collected from multiple centers between 1994 to may 1999.The study population included 561 patients (predominantly male, mean age 70 years), all of which were implanted with medtronic mosaic bioprosthesis (no serial numbers provided) in the atrial (461) or mitral position (100).Among all patients, adverse events included: structural valve deterioration, endocarditis, thromboembolism, nonstructural valve dysfunction, valve thrombosis, paravalvular leak (pvl), anti-thromboembolic hemorrhage, and reoperation or explant.Based on the available information medtronic product was associated with the adverse event(s).
|